Cargando…
Aronia in the Type 2 Diabetes Treatment Regimen
Aronia melanocarpa berries are rich in antioxidants and possess a high antioxidant capacity. Aronia berries have shown potential in type 2 diabetes mellitus (T2DM) treatment, and previous studies indicate improvements in glycemia after supplementation. Unfortunately, the effectiveness of aronia berr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574687/ https://www.ncbi.nlm.nih.gov/pubmed/37836472 http://dx.doi.org/10.3390/nu15194188 |
_version_ | 1785120750914502656 |
---|---|
author | Christiansen, Christine B. Jeppesen, Per B. Hermansen, Kjeld Gregersen, Søren |
author_facet | Christiansen, Christine B. Jeppesen, Per B. Hermansen, Kjeld Gregersen, Søren |
author_sort | Christiansen, Christine B. |
collection | PubMed |
description | Aronia melanocarpa berries are rich in antioxidants and possess a high antioxidant capacity. Aronia berries have shown potential in type 2 diabetes mellitus (T2DM) treatment, and previous studies indicate improvements in glycemia after supplementation. Unfortunately, the effectiveness of aronia berries is limited by the low bioavailability of aronia, which fermentation could potentially overcome. The objective of this study was to compare the effects of fermented or non-fermented aronia pulp with placebo in subjects with T2DM. This study was a triple-blinded, triple-crossover study with eight-week intervention periods with fermented aronia extract (FAE), non-fermented aronia extract (AE), and placebo. Extracts were incorporated in snack bars with 37% aronia (FAE or AE) or wheat bran (placebo) and 63% raisins and coconut oil. Pre- and post-treatment period, we did fasting blood samples, including hemoglobin A1c, fructosamine, insulin, glucose, glucagon-like peptide-1, glucose-dependent insulinotropic peptide (GIP) and glucagon, oral glucose tolerance tests, and anthropometric measurements. Of 36 randomized participants, 23 completed the trial. Aside from a higher increase in GIP after FAE supplementation compared to after placebo supplementation, aronia extracts had no effect. The increase in GIP levels after FAE supplementation may hold potential benefits, but the overall clinical impact remains unclear. |
format | Online Article Text |
id | pubmed-10574687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105746872023-10-14 Aronia in the Type 2 Diabetes Treatment Regimen Christiansen, Christine B. Jeppesen, Per B. Hermansen, Kjeld Gregersen, Søren Nutrients Article Aronia melanocarpa berries are rich in antioxidants and possess a high antioxidant capacity. Aronia berries have shown potential in type 2 diabetes mellitus (T2DM) treatment, and previous studies indicate improvements in glycemia after supplementation. Unfortunately, the effectiveness of aronia berries is limited by the low bioavailability of aronia, which fermentation could potentially overcome. The objective of this study was to compare the effects of fermented or non-fermented aronia pulp with placebo in subjects with T2DM. This study was a triple-blinded, triple-crossover study with eight-week intervention periods with fermented aronia extract (FAE), non-fermented aronia extract (AE), and placebo. Extracts were incorporated in snack bars with 37% aronia (FAE or AE) or wheat bran (placebo) and 63% raisins and coconut oil. Pre- and post-treatment period, we did fasting blood samples, including hemoglobin A1c, fructosamine, insulin, glucose, glucagon-like peptide-1, glucose-dependent insulinotropic peptide (GIP) and glucagon, oral glucose tolerance tests, and anthropometric measurements. Of 36 randomized participants, 23 completed the trial. Aside from a higher increase in GIP after FAE supplementation compared to after placebo supplementation, aronia extracts had no effect. The increase in GIP levels after FAE supplementation may hold potential benefits, but the overall clinical impact remains unclear. MDPI 2023-09-28 /pmc/articles/PMC10574687/ /pubmed/37836472 http://dx.doi.org/10.3390/nu15194188 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Christiansen, Christine B. Jeppesen, Per B. Hermansen, Kjeld Gregersen, Søren Aronia in the Type 2 Diabetes Treatment Regimen |
title | Aronia in the Type 2 Diabetes Treatment Regimen |
title_full | Aronia in the Type 2 Diabetes Treatment Regimen |
title_fullStr | Aronia in the Type 2 Diabetes Treatment Regimen |
title_full_unstemmed | Aronia in the Type 2 Diabetes Treatment Regimen |
title_short | Aronia in the Type 2 Diabetes Treatment Regimen |
title_sort | aronia in the type 2 diabetes treatment regimen |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574687/ https://www.ncbi.nlm.nih.gov/pubmed/37836472 http://dx.doi.org/10.3390/nu15194188 |
work_keys_str_mv | AT christiansenchristineb aroniainthetype2diabetestreatmentregimen AT jeppesenperb aroniainthetype2diabetestreatmentregimen AT hermansenkjeld aroniainthetype2diabetestreatmentregimen AT gregersensøren aroniainthetype2diabetestreatmentregimen |